Chiron Corporation

Novartis Vaccines & Diagnostics, Gmbh

Arrowhead Research Corporation

Relia Diagnostic Systems, LLC

The Director General of the National Institute of Health of Japan

Novartis Ag

Avirus, Inc.

Jang Hyun Han

Michael Houghton

Qui-Lim Choo

Amy J Weiner

Janice A Kolberg

Bruce D Irvine

Joonho Choe

Mark J Selby

William J Rutter

Byoung J Yoo

Taewoo Kwon

Michael S Urdea

George Kuo

David Y Chien

John M Polo

Richard R Spaete

Tatsuo Miyamura

John J Donnelly

Byung S Suh

Tai-An Cha

Izumi Saito

Mi-Young Seo

Yifei Zhu

Hyun Chul Song

Nicholas Valiante

Vega Masignani

Konrad Stadler

Mi Young Seo

Jens-Peter Gregersen

Rino Rappuoli

Hans Dieter Klenk

The disclosure provides recombinant polypeptides for treating or preventing viral infection comprising an immunoglobulin Fc fragment and at least one viral receptor or fragment thereof. Also provided are RNA molecules, therapeutic compositions, and expression systems comprising such recombinant polypeptides, along with methods of preventing or treating a viral infection in a subject in need thereof, comprising administering such recombinant polypeptides to a subject or patient.

Methods and compositions for treating and preventing viral infection

Described herein are systems and methods for the quantitative analysis of a sample comprising glycated hemoglobin. Also described herein are systems and methods for assaying a sample to quantitatively determine the percentage of glycated hemoglobin in the sample, for example, in a blood sample. The methods and systems described herein may be used in a point-of-care device as well as in other in vitro diagnostic devices.

Systems and methods for determining the percentage of glycated hemoglobin

The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer.

Modified small interfering RNA molecules and methods of use

The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer. The invention provides modified RNA molecules that are modified to include a dsRNA or siRNA wherein one or more of the pyrimidines in the RNA molecule are modified to include 2'-Fluorine. The invention also provides dsRNA or siRNA in which all pyrimidines are modified to include a 2&#x2032;-Fluorine. The invention provides that the 2&#x2032;-Fluorine dsRNA or siRNA molecule is further modified to include a two base deoxynucleotide 'TT' sequence at the 3&#x2032; end of the molecule.

Described herein are systems and methods for assaying a sample to quantitatively determine the percentage of glycated hemoglobin in the sample.

A tissue culture system for production of infectious hepatitis C virus is described. In particular, the invention provides recombinant monocistronic and bicistronic genomic constructs for production of virus, including constructs for production of wild-type HCV type 2a strain JFH1 and constructs for production of chimeric viruses comprising HCV proteins from strain JFH1 and a second HCV isolate. Constructs of the invention also include a reporter gene to facilitate measurement of RNA replication and viral infectivity in cultures. The cell culture system may also include various factors that improve viral replication or infectivity. In addition, a neutralization assay using HCV grown in cell culture is described.

Tissue culture system for production of hepatitis C virus

The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Detections from the amino terminus resulted in the protein becoming soluble. Deletions from the carboxy terminus do not result in a loss of helicase activity until at least 50 amino acids are deleted. The helicase activity requires ATP and divalent cations such as Mgand Mn. The helicase activity was blocked by monoclonal antibody specific to the HCV NS3 protein.

HCV NS3 protein fragments having helicase activity and improved solubility

Embodiments of the present invention feature methods and compositions for controlling the translation of viral peptides and proteins from viral nucleic acid, with particular applications to pestivirus and HCV. The methods and compositions feature control elements of the 5'UT region of the viral genome.

Methods and compositions for controlling translation of HCV proteins

The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Detections from the amino terminus resulted in the protein becoming soluble. Deletions from the carboxy terminus do not result in a loss of helicase activity until at least 50 amino acids are deleted. The helicase activity requires ATP and divalent cations such as Mg and Mn . The helicase activity was blocked by monoclonal antibody specific to the HCV NS3 protein.

The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Deletions from the amino terminus resulted in the protein becoming soluble. Deletions from the carboxy terminus do not result in a loss of helicase activity until at least 50 amino acids are deleted. The helicase activity requires ATP and divalent cations such as Mg,and Mn,. The helicase activity was blocked by monoclonal antibody specific to the HCV NS3 protein.

The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Detections from the amino terminus resulted in the protein becoming soluble. Deletions from the carboxy terminus do not result in a loss of helicase activity until at least 50 amino acids are deleted. The helicase activity requires ATP and divalent cations such as Mg.sup.2+ and Mn.sup.2+. The helicase activity was blocked by monoclonal antibody specific to the HCV NS3 protein.

HCV NS3 protein fragments having helicase activity and improved

Embodiments of the present invention feature methods and compositions for controlling the translation of viral peptides and proteins from viral nucleic acid, with particular applications to pestiviras and HCV. The methods and compositions feature control elements of the 5'UT region of the viral genome.

Growing community of inventors

Lafayette, CA, United States of America

Jang Hyun Han